# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Audre Lorde (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML016-SYN-TD
- Date: 1979-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Naomi Fairweather, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

Primary care survivorship visit five and a half months after right mastectomy for stage IA breast cancer, on tamoxifen. **S**

## Historical basis

- Audre Lorde was born Audrey Geraldine Lorde on February 18, 1934, in New York City; her parents were immigrants from Grenada. **D**
- Lorde was a poet, essayist, and novelist. In her poetry and prose she wrote about matters important to her as a woman of color, as a lesbian, as a mother, and as a feminist; a reference biography describes her as an African American lesbian feminist and poet. **D**
- In 1977 a doctor found a tumor in Lorde's breast that, after about three weeks of uncertainty, proved benign. In a talk given that year to the Modern Language Association she said: "Your silence will not protect you." **D**
- On Labor Day 1978, during a routine self-examination, Lorde found a lump in her right breast; a diagnosis of malignancy and a mastectomy followed. She described the experience in The Cancer Journals. **D**
- After her mastectomy Lorde chose never to hide the fact of her missing breast. She refused to wear the "wad of lambswool pressed into a pale pink breast-shaped pad" pushed on her by nurses and medical counselors, and she was repeatedly scolded for posing a threat to cancer patient "morale." **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Moving her breast cancer survivorship care to primary care, with the oncology team kept informed; mild hot flashes on tamoxifen. **S**
- Wants complete information and to make her own decisions. She chose a flat closure without reconstruction and does not wish to wear an external prosthesis; she asks that this not be raised again unless she raises it. **S**

## Strengths and supports

- Supports: her family and a wide circle of writers and friends **S**

## Medications and allergies

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1977: Breast tumor found by a doctor, benign after about three weeks of uncertainty **D** (CLM-0003)
- 1978: Lump in the right breast found at self-examination on Labor Day, followed by a diagnosis of breast cancer and a mastectomy; she declined a breast prosthesis **D** (CLM-0004, CLM-0005)

## Procedures and immunizations

- 1978-09-08 to 1978-09-08: Diagnostic bilateral mammography after a self-detected right breast lump: 1.6 cm irregular mass in the upper outer right breast, BI-RADS 5; left breast normal **S**
- 1978-09-08 to 1978-09-08: Right breast and axillary ultrasound: 1.6 cm irregular hypoechoic mass at 10 o'clock; normal axillary lymph nodes **S**
- 1978-09-10 to 1978-09-10: Ultrasound-guided core needle biopsy of the right breast mass: invasive ductal carcinoma, grade 2; ER 90 percent, PR 60 percent, HER2 1+ (negative), Ki-67 12 percent **S**
- 1978-09-26 to 1978-09-26: Right total mastectomy with flat closure and no reconstruction, her informed choice. Pathology: invasive ductal carcinoma 1.6 cm, grade 2, margins clear, no lymphovascular invasion; pT1c pN0(sn), stage IA. Recurrence score (21-gene assay) 14 **S**
- 1978-09-26 to 1978-09-26: Right axillary sentinel lymph node biopsy at mastectomy: 0 of 2 nodes involved **S**
- 1978-10-14: Influenza vaccine, 1978-1979 season **S**
- 1972-05-06: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

PHQ-9: 4; GAD-7: 3. All results are synthetic.

BP 124/78 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 72 kg; BMI 25.5 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, articulate, and direct; asks for complete information and makes her own decisions about her care; Mood euthymic; PHQ-9 and GAD-7 in the minimal range. Functional status: Independent in all activities of daily living; full range of motion of the right shoulder; writing and walking daily. Physical examination is intentionally limited. **S**

## Assessment

1. Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1931 breast cancer and mastectomy; status draft. **S**
2. Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent); status draft. **S**
3. Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesis; status draft. **S**
4. Long-term use of tamoxifen as adjuvant endocrine therapy; status draft. **S**

## Plan

- Medical oncology consultation to confirm the adjuvant endocrine therapy plan, advise on hot flashes, set the surveillance plan, and advise on genetic assessment. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019) **S**
- Tamoxifen 20 mg daily for at least five years, with questions at every visit about hot flashes, abnormal vaginal bleeding, and leg swelling or breathlessness, and a yearly gynecologic assessment. Guideline: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Lymphedema risk counseling and arm checks at every visit; bone health by calcium and vitamin D from diet and weight-bearing exercise; distress, depression, and anxiety screening at intervals. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Written survivorship care plan, at least 150 minutes of activity a week, alcohol at or below one drink a day, and her decisions about reconstruction and a prosthesis recorded and respected. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016), American Cancer Society and American Society of Clinical Oncology
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge
